Compare Devonian Health Group, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
CAD 33 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.69
-22.15%
3.46
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Oct 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5066.67%
0%
5066.67%
6 Months
6100.0%
0%
6100.0%
1 Year
8757.14%
0%
8757.14%
2 Years
5804.76%
0%
5804.76%
3 Years
1966.67%
0%
1966.67%
4 Years
2430.61%
0%
2430.61%
5 Years
10233.33%
0%
10233.33%
Devonian Health Group, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
44.99%
EBIT Growth (5y)
8.22%
EBIT to Interest (avg)
-2.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
1.40
Tax Ratio
10.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.64%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.46
EV to EBIT
-14.81
EV to EBITDA
-17.72
EV to Capital Employed
8.85
EV to Sales
1.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-59.74%
ROE (Latest)
-22.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Oct'25 - YoY
Oct'25
Oct'24
Change(%)
Net Sales
1.10
6.10
-81.97%
Operating Profit (PBDIT) excl Other Income
-1.60
-0.50
-220.00%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.60
-0.60
-166.67%
Operating Profit Margin (Excl OI)
-1,514.70%
-93.00%
-142.17%
USD in Million.
Net Sales
YoY Growth in quarter ended Oct 2025 is -81.97% vs 369.23% in Oct 2024
Consolidated Net Profit
YoY Growth in quarter ended Oct 2025 is -166.67% vs 14.29% in Oct 2024
Annual Results Snapshot (Consolidated) - Jul'25
Jul'25
Jul'24
Change(%)
Net Sales
23.60
19.30
22.28%
Operating Profit (PBDIT) excl Other Income
-0.40
0.10
-500.00%
Interest
0.30
0.40
-25.00%
Exceptional Items
-4.80
0.00
Consolidate Net Profit
-6.00
-1.80
-233.33%
Operating Profit Margin (Excl OI)
-32.70%
-31.80%
-0.09%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
About Devonian Health Group, Inc. 
Devonian Health Group, Inc.
Pharmaceuticals & Biotechnology
Devonian Health Group In is a late stage Canada-based botanical and pharmaceutical company. The Company adopts a therapeutic approach, which targets various worldwide unmet medical needs. The core business of the Company is the development of prescription botanical drugs, as well as derma-cosmeceutical products, which is divided into two main segments: Therapeutics and Derma-cosmeceuticals. The Therapeutics segment includes Thykamine, which is an active lead drug candidate confirmed in a number of pre-clinical and clinical studies targeting inflammation. The Derma-cosmeceuticals includes the first derma-cosmeceutical product of the Company, which is a women’s anti-aging treatment consisting of day, night and eye creams.
Company Coordinates 
Company Details
115 Frontenac Ave , POINTE-CLAIRE QC : H9R 4Z7
Registrar Details






